GlassScriptPhysician profile
Bruce S Mather
NPI 1053399071
$12,758.65
in general payments reported to CMS, 2019-2025
70 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $1,154 · 2021: $1,940 · 2022: $1,814 · 2023: $2,361 · 2024: $2,446 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,835.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,725.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,208.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,118.92 | 2019-2025 | |
| Abbvie INC. | $1,063.15 | 2019-2025 | |
| Amgen INC. | $812.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $730.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $578.52 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.80 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $464.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $332.29 | 2022-2025 | |
| Esperion Therapeutics, INC. | $279.25 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $245.30 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $230.64 | 2019-2024 | Xarelto |
| Abbott Laboratories | $223.47 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $220.37 | 2019-2023 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Mather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.